AR113804A1 - FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR - Google Patents

FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR

Info

Publication number
AR113804A1
AR113804A1 ARP180103132A ARP180103132A AR113804A1 AR 113804 A1 AR113804 A1 AR 113804A1 AR P180103132 A ARP180103132 A AR P180103132A AR P180103132 A ARP180103132 A AR P180103132A AR 113804 A1 AR113804 A1 AR 113804A1
Authority
AR
Argentina
Prior art keywords
macrocyclic
formulations
pharmaceutical composition
kinase inhibitor
trk kinase
Prior art date
Application number
ARP180103132A
Other languages
Spanish (es)
Inventor
Charles Todd Eary
Julia Haas
Yutong Jiang
Stacey Spencer
Qian Zhao
Original Assignee
Array Biopharma Inc
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Loxo Oncology Inc filed Critical Array Biopharma Inc
Publication of AR113804A1 publication Critical patent/AR113804A1/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica que comprende un compuesto de fórmula (1) y un agente de composición acuoso que comprende celulosa microcristalina, carboximetilcelulosa sódica, goma de xantano, carragenina o una combinación de las mismas. Reivindicación 2: La composición farmacéutica de conformidad con la reivindicación 1, caracterizada porque comprende además al menos uno de ácido cítrico, un citrato, un lactato, un fosfato, un maleato, un tartrato, un succinato, un sulfato o un acetato. Reivindicación 90: Una composición para uso es para tratar un cáncer asociado a Trk en un sujeto, la composición que comprende una cantidad terapéuticamente efectiva de la composición farmacéutica de conformidad con cualquiera de las reivindicaciones 1 - 17.Claim 1: A pharmaceutical composition comprising a compound of formula (1) and an aqueous compounding agent comprising microcrystalline cellulose, sodium carboxymethyl cellulose, xanthan gum, carrageenan or a combination thereof. Claim 2: The pharmaceutical composition according to claim 1, characterized in that it further comprises at least one of citric acid, a citrate, a lactate, a phosphate, a maleate, a tartrate, a succinate, a sulfate or an acetate. Claim 90: A composition for use is to treat a Trk-associated cancer in a subject, the composition comprising a therapeutically effective amount of the pharmaceutical composition according to any of claims 1-17.

ARP180103132A 2017-10-26 2018-10-26 FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR AR113804A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762577449P 2017-10-26 2017-10-26

Publications (1)

Publication Number Publication Date
AR113804A1 true AR113804A1 (en) 2020-06-10

Family

ID=71523231

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103132A AR113804A1 (en) 2017-10-26 2018-10-26 FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR

Country Status (1)

Country Link
AR (1) AR113804A1 (en)

Similar Documents

Publication Publication Date Title
BR102016017090B8 (en) LOW PH TOPICAL COMPOSITION AND METHOD TO INCREASE THE TOPICAL APPLICATION OF A COSMETICALLY ACCEPTABLE ACTIVE INGREDIENT
AR107828A1 (en) 2-AMINO-N- [7-METOXI-2,3-DIHYDROIMIDAZO- [1,2-C] QUINAZOLIN-5-IL] PYRIMIDIN-5-CARBOXAMIDS AS A PI3K INHIBITOR
MX2022013612A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies.
MX2015016421A (en) Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease.
UY31080A1 (en) PIRAZOL DERIVATIVES REPLACED WITH HETEROARILE USEFUL TO TREAT HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
MX2015016425A (en) Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease.
MX2020005942A (en) Oral thin film with high active agent loading.
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
MX2016000727A (en) Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition.
MX2022001789A (en) 2-hydroxycycloalkane-1-carbamoyl derivatives.
EA201690077A1 (en) THERAPEUTICALLY ACTIVE DERIVATIVES OF ESTRATRIEN-THIAZOLE
PE20061390A1 (en) SUBEROYLANILIDE HYDROXAMIC ACID FORMULATIONS AND PROCEDURES FOR THE PRODUCTION OF THE SAME
BR112019007863A2 (en) innovative naphthyridinone derivatives and their use in the treatment of arrhythmia
MX2020001399A (en) Antifungal agents with enhanced activity in acidic ph.
BR112012015170A8 (en) AMINOHETEROARYL DERIVATIVE, PHARMACEUTICAL COMPOSITION, USE OF AN AMINOHETEROARYL DERIVATIVE, AND METHOD FOR TREATMENT OF PAIN
AR087371A1 (en) FORMULATIONS OF (TRIMETOXIFENILAMINO) PYRIMIDINYL, METHODS
AR113804A1 (en) FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
BR112015017628A2 (en) use of phenoxypropylamine compounds to treat depression
MX2019004576A (en) Pharmaceutical compositions.
AR086252A1 (en) TOPICAL FORMULATION THAT INCLUDES BECLOMETASONE DIPROPIONATE AS ACTIVE INGREDIENT
EP3636642A8 (en) Indoleacetic acid derivative and preparation method and pharmaceutical use thereof
AR100920A1 (en) ANTIMICROBIAL COMPOSITIONS WITH EFERVESCENT AGENTS, METHOD
AR062674A1 (en) WATERY FORMULATION UNDERSTANDING AN ANTITUMORAL AGENT
PH12015502560A1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease
EA202192107A1 (en) TRITERPENOID FUNGICIDES FOR TREATMENT OF FUNGAL BONE-JOINT INFECTIONS

Legal Events

Date Code Title Description
FB Suspension of granting procedure